Data from Sonata® Technology Platform Featured in Presentations at AAGL Global Congress in Orlando

First Health Economic Outcomes Research with Sonata Treatment to be

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, a women’s healthcare company focused on the development of
advanced incision-free solutions for the treatment of uterine
conditions, today announced that its Sonata® System technology platform
for transcervical incision-free treatment of uterine fibroids will be
featured in four presentations at the 45th Annual American
Association of Gynecologic Laparoscopists (AAGL) Global Congress
November 14-18 at the Rosen Hotel at Shingle Creek in Orlando, Florida.
The AAGL is the leading association promoting minimally invasive
gynecologic surgery among surgeons worldwide. Its membership extends to
more than 110 countries and more than 7,000 members globally.

The presentations will include the first health economic outcomes data
based on treatment with the Sonata System, an incision-free,
transervical treatment for uterine fibroids that preserves the uterus,
noted Gynesonics President and CEO Christopher M. Owens.

“This data is critically important to our global reimbursement strategy
and to providers and payers, “ Owens said. “We are building upon the
impressive clinical outcomes being achieved with Sonata. Providing the
associated health economic outcomes research, essential to validating an
innovative technology, is one additional piece. As a company, Gynesonics
is committed to providing the gynecology community a new incision-free,
transcervical, uterus preserving option for the treatment of symptomatic
uterine fibroids.”

Topics and presenters include:



Wednesday, 16 November

Session: Open Communication 04 – New Instrumentation or
Technology, Room: Panzacola G-2



Intrauterine Sonography Guided Transcervical RF-Ablation of
Symptomatic Uterine Fibroids: Results of a New Therapeutic Option
in a Single Institution,” Ralf Bends, M.D., Protestant Hospital,
Cologne-Weyertal, Germany



Improvement in Health Utility After Transcervical Radiofrequency
Ablation of Uterine with the Sonata System, Elizabeth Brooks,
Ph.D., Decision Driver Analytics, Asheville, NC



Early Results of the SONATA Study: Sonography Guided Transcervical
Ablation of Uterine Fibroids, Kelly Roy, M.D., Arizona Gynecology
Consultants, Phoenix, Arizona.


Thursday, 17 November

Session: Open Communication 19 – New Instrumentation or
Technology, Room: Panzacola G-2



Pregnancy Outcomes Following Hyperthermic Fibroid Ablation, Julia
G. Keltz, MD, Montefiore Medical Center, Bronx, NY


About Sonata System

The Sonata System, the next generation of Gynesonics’ fibroid treatment
platform (the previous generation referred to as VizAblate), uses
radiofrequency energy to ablate fibroids under intrauterine sonography
guidance. The Sonata System, including the SMART Targeting Guide,
enables the operator to target and ablate fibroids. Sonata System’s
design provides a straightforward, transcervical access for a uterus
preserving, incision-free fibroid treatment. This intrauterine approach
is designed to avoid the peritoneal cavity.

About Gynesonics

Gynesonics is a women’s healthcare company focused on advanced
incision-free solutions for treatment of uterine conditions. Gynesonics
has developed the Sonata System for the transcervical treatment of
symptomatic uterine fibroids under intrauterine sonography guidance. The
Sonata System is CE Marked and approved for sale in the European Union.
Sonata System is not available for sale in the United States. Gynesonics
is a privately held company with headquarters in Redwood City, CA.


Chris Owens, +1.650.216.3860
President and CEO